The Fort Lauderdale, Florida–based company develops the Mantra platform of surgical robots, with the latest version coming in the form of its Mantra 3. The company launched Mantra 3 earlier this year and initiated the regulatory process in the U.S. and Europe. It hopes for approvals in the latter half of 2025.
Mantra 3 provides capabilities for multi-specialty usage, including in cardiothoracic, head and neck, gynecology, urology, and general surgery.
Doctors performed a bilateral IMA coronary artery bypass graft and ASD repair and beating heart totally endoscopic coronary artery bypass (TECAB) at the Harapan Kita National Cardiac Hospital in Jakarta. The company said its latest case in Indonesia marks a milestone for both the country and for its own state-of-the-art surgical robot. Dr. Sudhir Srivastava, founder, chair and CEO of SS Innovations, performed the TECAB procedure.
The company believes the launch of its robotic cardiac surgery program in Indonesia “represents the beginning of a new era of cardiac care” there. After the initial TECAB case, the company and Harapan Kita’s surgical team performed a number of other procedures over the following days.
“Reaching this milestone with SSi Mantra is a testament to our vision of transforming surgical practices, enhancing access, and driving the global adoption of cost-effective robotic surgery,” Srivastava said. “This collaboration addresses the critical need for safe, timely, and affordable cardiac care while offering patients less invasive options and an improved quality of life. The successful use of SSi Mantra in cardiac surgeries positions the company to accelerate momentum, gain market share in key markets, and continue our mission of making affordable robotic surgery accessible to patients worldwide.”
